Breakthrough in Brain Health: Game-Changing Funding Injects Hope!

Innovative Ultrasound Technology Poised to Transform Neurodegenerative Disease Treatment

2 mins read

Key Takeaways:

  • Carthera secures an additional €4.5M in funding, totaling €42M, for its groundbreaking SonoCloud® technology.
  • First US VC, Unorthodox Ventures, joins the investment, bolstering international support.
  • Funds to advance a pivotal trial in recurrent glioblastoma treatment and expand research in neurodegenerative diseases.

A Leap Forward in Neurological Care Paris, France, stands at the forefront of a significant advancement in medical technology for brain disorders. Carthera, a promising spin-off from Sorbonne University, has secured an additional €4.5 million to its Series B financing round, culminating in a substantial €42 million investment. This infusion of capital marks a critical phase in the development of its revolutionary SonoCloud® technology, an ultrasound-based medical device designed to combat a wide spectrum of brain disorders.

The Catalysts of Change: Investors Rallying for a Cause Joining this financial journey is the first US-based venture capital firm, Unorthodox Ventures, known for its unconventional approach to supporting groundbreaking ideas. Alongside Unorthodox Ventures, existing shareholders such as Supernova Invest, Saint-Genys, and Bouscas Med have reinforced their commitment to Carthera’s vision, acknowledging the potential impact of its technology on global health.

The Mission: Pioneering Treatment for Glioblastoma Carthera’s immediate goal is to channel these funds into launching its first registrational trial focusing on recurrent glioblastoma (rGBM) treatment. This international, multicenter, two-arm clinical trial will provide a comparative analysis of the SonoCloud-9® system’s effectiveness against standard care methods in enhancing overall survival rates for patients with GBM recurrence.

Voices of Confidence and Support Carey Smith, the Founding Contrarian of Unorthodox Ventures, commends Carthera’s technology for addressing a critical health issue. Celia Hart, General Partner at Supernova Invest, echoes this sentiment, praising the company’s continuous positive results in treating recurrent glioblastoma with the SonoCloud device. Their reinforcement of support through this financing round speaks volumes of their faith in Carthera’s mission.

See also  Shocking Revelation: UK Businesses Clueless About AI Benefits Despite Surging Investments!

Expanding Horizons: Beyond Glioblastoma Apart from focusing on glioblastoma, the company is also setting its sights on the broader field of neurodegenerative diseases. This expansion includes developing both clinical and preclinical pipelines, actively seeking collaborations with pharmaceutical and biotech partners to leverage SonoCloud technology for delivering therapies to the brain.

SonoCloud®: A Glimpse into the Future SonoCloud stands as a testament to innovative medical advancement. Developed in collaboration with the Laboratory of Therapeutic Applications of Ultrasound (LabTAU, INSERM) in Lyon, France, this implantable device emits ultrasound to temporarily enhance the permeability of brain blood vessels. This technological marvel allows for increased concentration of therapeutic molecules in the brain, offering new avenues of treatment for various brain disorders, including tumors and Alzheimer’s disease.

The Investors: Driving Innovation Forward Unorthodox Ventures, led by Big Ass Fans Founder Carey Smith, takes a unique approach in supporting entrepreneurs. Beyond financial backing, it offers comprehensive support in multiple business areas, reflecting a new paradigm in the investment process. Similarly, Supernova Invest, the leading deep tech venture capital firm in France, boasts a portfolio of 80+ impact startup companies. Their long-standing commitment to supporting sustainable growth in deep tech and industrial champions is evident in their continued support of Carthera.

About Carthera: At the Helm of Medical Innovation Founded in 2010 by neurosurgeon Pr. Alexandre Carpentier, Carthera represents the convergence of medical expertise and innovative thinking. With CEO Frederic Sottilini at the helm and Oern Stuge MD as the chairman, the company has established itself as a pioneer in developing ultrasound-based medical devices. Its operations span across France and the United States, reflecting its global ambition and commitment to revolutionizing brain health.

See also  The Power of Place: How This Mega Merger is Set to Redefine European Business Strategies

For detailed information on Carthera and its groundbreaking work, visit Carthera’s website.


Sign up to our newsletter & get the most important monthly insights from around the world.


Ready to Amplify Your Brand with Business Today?

Discover the power of sponsored articles and partnerships to reach decision-makers, professionals, and a dynamic audience. Learn more about our advertising opportunities and connect with us today!

Click here to explore our Promotion & Sponsored Articles page.

Are you looking to make an impact? Contact us at [email protected] to get started!

See also  Shocking Revelation: UK Businesses Clueless About AI Benefits Despite Surging Investments!

Business Today News

BusinessToday.news is an online publication committed to delivering comprehensive and insightful coverage of the latest business news, trends, and practices. With a focus on finance, technology, entrepreneurship, and other critical areas, it serves as a valuable resource for professionals seeking to stay abreast of the rapidly evolving business landscape.

Leave a Reply

Your email address will not be published.

Latest from Blog

About

BusinessToday.news is a premier online platform dedicated to providing the latest news and insights on a wide range of topics related to the business world, including technology, finance, real estate, healthcare, and more.

Newsletter

Copyright Unstructured.Media. All rights reserved. Explore our sitemap